Industry
Biotechnology
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Loading...
Open
1.75
Mkt cap
50M
Volume
54K
High
1.83
P/E Ratio
-2.19
52-wk high
7.75
Low
1.70
Div yield
N/A
52-wk low
1.26
Portfolio Pulse from Benzinga Newsdesk
February 06, 2024 | 8:38 am
Portfolio Pulse from Benzinga Newsdesk
February 05, 2024 | 8:39 pm
Portfolio Pulse from Benzinga Newsdesk
February 05, 2024 | 8:34 pm
Portfolio Pulse from Benzinga Newsdesk
February 05, 2024 | 8:33 pm
Portfolio Pulse from Benzinga Newsdesk
February 05, 2024 | 8:22 pm
Portfolio Pulse from Benzinga Newsdesk
February 05, 2024 | 8:21 pm
Portfolio Pulse from Benzinga Insights
January 25, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Insights
December 15, 2023 | 5:31 pm
Portfolio Pulse from Benzinga Insights
December 14, 2023 | 5:32 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.